Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study-Reference-Cited by-同舟云学术

Gefitinib (IRESSA) in Patients of Asian Origin with Refractory Advanced Non-small Cell Lung Cancer: Subset Analysis from the ISEL Study

Published:2006-10 Issue:8 Volume:1 Page:847-855
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Chang Alex,Parikh Purvish,Thongprasert Sumitra,Tan Eng Huat,Perng Reury-Perng,Ganzon Domingo,Yang Chih-Hsin,Tsao Chao-Jung,Watkins Claire,Botwood Nick,Thatcher Nick

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference31 articles.

1. Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

2. Specific inhibition of epidermal growth factor receptor tyrosine kinase by 4-anilinoquinazolines

3. Multi-Institutional Randomized Phase II Trial of Gefitinib for Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer

4. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non–Small Cell Lung Cancer

Cited by 161 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. To Investigate Growth Factor Receptor Targets and Generate Cancer Targeting Inhibitors;Current Topics in Medicinal Chemistry;2023-12

2. Dealing with censoring in a network meta-analysis of time-to-event data;Research Methods in Medicine & Health Sciences;2023-07-14

3. Clinical outcomes of chemotherapy in cancer patients with different ethnicities;Cancer Reports;2023-05-07

4. A Review of the Evolving Landscape of Inclusive Research and Improved Clinical Trial Access;Clinical Pharmacology & Therapeutics;2023-01-26

5. Influence of Smoking Habits on the Efficacy of EGFR-TKI Therapy in Patients with Advanced NSCLC: A Systematic Review and Meta-Analysis;Clinical Medicine Insights: Oncology;2023-01